Research is typically done on single agents, but in practice, medications are most often used in combination. This Clinical Guide offers a way to model/ predict the effects of medication combinations.
Although the theory is complex and supported by hundreds of citations from the medical literature, the practical question is how to treat a patient's symptoms. This document links symptoms in traditional ROS format to apparent purine imbalances (search the site for basic literature review) and medications that may tend to alleviate (or exacerbate) those imbalances.
I recommend writing deficit/excesses from pg1 onto the letters on pg 2, then highlighting the current medications, then considering medication changes.
Each capital letter represents a purine, while lines/arrows represent purine metabolism enzymes that seem to be activated or inhibited by various listed medications, based on a combination of chemical structure and clinical experience. The details of which purine and which enzyme are understated in this chart to provide maximum attention to treatment. There are some purines available as dietary supplements, including SAM-e (X), Inosine (J), and NAD. SAM-e has literature support for psychiatric clinical use.
These charts have helped me to more accurately predict response to complicated combinations of medicines and symptoms. I have been able to watch in detail as symptoms are transformed, then resolved.
My hope is that providers can join me in using this theory as an additional way to formulate symptoms and treatment. Agents noted as unnecessarily opposing each other may be able to be streamlined. Specific agents within current accepted clinical practice may be prioritized in order to more precisely target and treat symptoms. Where traditional recommendations have been exhausted, similarities in chemical structure or apparent effect may point to off-label options.
I recently treated a woman in her late 50s who had been transferred to long-term hospitalization after failing to respond to treatment for depression during a 30+ day acute hospitalization.
Description from OSH nursing included a description of her face becoming a 'mask' early on in the hospitalization, with limited progress (and possible worsening) since that time.
ROS demonstrated a variety of syndromes: Parkinsonian gait, akathisia, suicidal thoughts, edema, tremor, depression, difficulty with sleep initiation and continuation, OCD, and fungal infection. Treatment with high-dose SSRI, SNRI, and three low-dose antipsychotics for augmentation and sleep was not helping.
There are multiple rationales that can be put forward for taking the next steps: notes can include isolated medically-acceptable reasons rather than propounding the purine theory of psychiatry.
In many cases, there are symptoms of excess that could be targeted to resolve both an excess and deficit at the same time. These steps should be prioritized if possible.
Discontinuation of antipsychotics:
avoid contributing to/ worsening Parkinsonian symptoms
inadequate response despite continued use
D- deficit is in the lower left-hand corner is the most physiologically pressing, and antipsychotics may function by reducing or blocking D = guanine
SAM-e supplement: 400-800mg BID
depression treatment/ augmentation strategy unlikely to contribute to Parkinsonian symptoms
augment purine intake in order to provide raw material (in addition to dietary sources) to address deficits (including O: sleep initiation), since no excesses are available. Represented by X on the Clinical Guide
Add ondansetron 4-8mg BID
treat potential nausea/ improve appetite
off-label treatment for anxiety
low-risk agent with pre-clinical data suggesting improvement for Parkinsonian symptoms PMID 30656239
augment conversion to B, C, and D. Connecting ondansetron dose to SAM-e dose reduces risk of secondary I, J, K deficits
Cross-taper antidepressant to sertraline
trial an alternative SSRI
different than other antidepressants, sertraline increases flow from beyond-L to more fundamental purines
Add clonidine 0.1-0.2mg BID
non-BZD treatment for anxiety and sleep unlikely to increase Parkinsonian symptoms
increase conversion to D, H, and K, addressing the urgent D-deficit (Parkinsonian symptoms) and K deficit (suicidal thoughts and edema). Increasing flow through L will also allow for refilling of non-Z letters beyond L, once the more pressing deficits are filled. (In PD, SAM-e (X) is low prior to treatment, increases following treatment PMID 16340382. Metabolism enzymes moving toward D are upregulated as PD progresses PMID 25597950 )
Cross-taper sertraline to fluoxetine (selected to address residual OCD symptoms)
side-effects
trial a different SSRI
after pre-L deficits significantly resolved, sertraline-augmented flow was no longer needed and contributed to hyperventilation, which resolved on discontinuation, recurred with accidental restart by cross-cover
Briefly supplement magnesium
improve sleep/ mood; discontinue due to loose stools
ensure Q adequacy
Add melatonin for sleep
Parkinsonian gait D: stride noticeably lengthened within 1 week, 180 degree turn reduced from 9 steps to 6 steps (wk1) then 4 steps (wk2) and did not recur in the next > 2mos
Tremor C: noticeably less (wk1,2), then intermittent (wk3). Resolved (wk4) and did not recur
OCD I: resolved (wk2), then recurred (wk3), responded to transition to fluoxetine and titration (wk4,5). Resolved (wk6) and did not recur
Depression J: mood and energy improved (wk1), participating in some group therapy (wk2,3,4), >4hrs/day (wk5) without feeling exhausted afterwards (wk6)
Suicidal thoughts K: from all-day every-day to sometimes (wk1) to <3x/ wk (wk2) 1x/wk (wk3), none (wk4), recurrence to <3x/wk (wk5,6), then resolved and did not recur
Edema K: decreased (wk1,2,3) resolved (wk4) and did not recur
Akathisia P: improved (wk1,2), then resolved and did not recur
Difficulty with sleep initiation and continuation O, D: noticeably improved (wk1) despite discontinuation/ taper of several targeting agents, added melatonin (wk2), and did not recur
Fungal infection L: non-compliant with topical antifungal, gradually noticed improvement from apparent improved immune function.